Title:
CHIMERIC ANTIGEN RECEPTOR TARGETING CD5 AND IMMUNE CELLS EXPRESSING SAME
Document Type and Number:
WIPO Patent Application WO/2024/076121
Kind Code:
A1
Abstract:
The present invention relates to immune cells co-expressing IL-15 and a chimeric antigen receptor comprising an OX40 ligand as an intracellular signaling domain, and to a composition for preventing or treating cancer comprising same as an active ingredient. The immune cells according to the present invention not only exhibit synergistic tumor cell killing activity through co-expression of the chimeric antigen receptor and IL-15, but also significantly improve survival and in vitro proliferation rates, and can thus be usefully employed as an efficient anti-cancer cell therapy. In particular, when the immune cells of the present invention express a chimeric antigen receptor targeting CD5, the immune cells can be used as an effective treatment composition for various CD5-positive tumors, including lymphocytic leukemia.
Inventors:
KIM SEUNG MIN (KR)
LEE EUNSOL (KR)
SUN HYUN SEUNG (KR)
KIM HANSOL (KR)
CHO SUNGLIM (KR)
JUNG MIYOUNG (KR)
MIN BOKYUNG (KR)
LEE EUNSOL (KR)
SUN HYUN SEUNG (KR)
KIM HANSOL (KR)
CHO SUNGLIM (KR)
JUNG MIYOUNG (KR)
MIN BOKYUNG (KR)
Application Number:
PCT/KR2023/015186
Publication Date:
April 11, 2024
Filing Date:
October 04, 2023
Export Citation:
Assignee:
GC CELL CORP (KR)
International Classes:
C07K14/725; A61K35/17; A61K39/00; A61P35/02; C07K14/54; C07K14/705; C07K16/28; C12N5/0783; C12N15/62
Attorney, Agent or Firm:
PADO IP LAW PLLC (KR)
Download PDF: